ASX ANNOUNCEMENT

Lumos Diagnostics Annual General Meeting
Chair's Address

MELBOURNE, Australia (13 November 2026) – Lumos Diagnostics Holdings Ltd (ASX: LDX, "Lumos" or the "Company"), a leader in rapid, point-of-care diagnostic technologies, today releases it's Chair's Address for the 2026 Annual General Meeting as follows:

Good morning, fellow shareholders, and thank you for joining us today. My name is Sam Lanyon, the Chair of Lumos Diagnostics.

Let me start by saying that FY26 was a defining year for Lumos Diagnostics and, in many respects, one of the most important in our Company's history.

The standout achievement was the receipt of FDA CLIA waiver clearance for our proprietary FebriDx® test, a milestone that expanded our addressable U.S. market opportunity more than fifteen-fold to over US$1 billion. This milestone represents the culmination of many years of our team's innovation and regulatory efforts, advancing the widespread commercialisation of a solution designed to address a significant unmet clinical need. This now provides the foundation for broad adoption of FebriDx across urgent care centres, physician offices and other point-of-care settings throughout the United States.

Importantly, FY26 was not simply a year of regulatory success. It was a year in which we began building the commercial framework needed to convert that success into meaningful shareholder value creation.

We advanced our relationships with key partners including PHASE Scientific, PRO-spectus, AcuityMD and CG Life, while expanding reimbursement coverage, a critical requirement for broader adoption. FebriDx is now included on the national Medicare fee schedule at US$41.38 per test, with recognition across all Medicare Administrative Contractors. We have also continued to engage positively with private payors as we work to expand the reimbursement pathway required for long-term commercial success.

What is particularly encouraging is that we are now seeing tangible evidence that these efforts are translating into growing market momentum.

As at 11 October 2026, FebriDx was live across 265 clinical sites, spanning 29 U.S. states, representing an estimated 1.1 to 1.5 million annual acute respiratory infection (ARI) patient visits. More than 90% of those patient encounters were covered by established payment pathways at the current Medicare reimbursement rate. This growing installed base provides both validation of the product's clinical value and a platform for future growth.

Beyond those live sites, our commercial pipeline continues to expand. This week, we announced Wellstreet's intention to roll FebriDx out across all of its sites by the end of calendar year 2026. We also currently have 485 sites in active evaluation, representing a further estimated 1.9 to 2.7 million ARI patient

visits, including eight of the top 100 urgent care groups in the United States. Pleasingly, since our update in mid-September, we have added a further 50 live sites, expanded into three additional states and increased evaluation sites by approximately 80 locations.

Alongside commercial execution, we continue to invest in expanding the clinical utility of FebriDx. During the year, we commenced our paediatric study in children aged 2 to 12 years. Success in this program would broaden the addressable market and further strengthen FebriDx's value proposition across primary care and urgent care settings.

Our Services business also continued to make important progress during FY26. We advanced our collaboration with Hologic on its next-generation fetal fibronectin point-of-care diagnostic test, while securing additional development opportunities with customers seeking expertise in assay development, manufacturing and commercialisation. This business remains an important strategic asset, providing revenue diversity while reinforcing Lumos' reputation as a high-quality, reliable partner to leading diagnostic organisations.

From a financial standpoint, we strengthened our capital position during the year, providing the flexibility required to support commercial expansion of FebriDx and ensure operational readiness as demand increases. Importantly, we remain disciplined in our approach to capital allocation and focused on deploying resources where they can generate the greatest long-term return for shareholders.

As we look ahead to FY27, our priorities are clear. We will continue driving adoption of FebriDx across the U.S. healthcare market, convert evaluation programs into live network rollouts, expand reimbursement coverage, advance our paediatric program and deepen relationships in our Services business with both existing and new partners.

While there is still significant work ahead, we believe Lumos enters this next phase from a position of increasing strength.

On behalf of the Board, I thank our shareholders for your continued support and confidence. I also extend our sincere appreciation to the customers adopting FebriDx and the clients who entrust our Services business with critical development programs.

Finally, I would like to thank Doug Ward, the leadership team and all Lumos employees. Your dedication, resilience and commitment have been instrumental in achieving the milestones of the past year and will be equally important as we pursue the opportunities that lie ahead.

Thank you.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics (ASX: LDX) specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:
Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 423 139 163

Investor Contact:
George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:
Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000
info@lumosdiagnostics.com
+61 3 9087 1598